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Abstract
Systemic sclerosis (SSc) is a connective tissue disease
characterized by tissue fibrosis. One of several complications of
SSc, pulmonary arterial hypertension (PAH) can be refractory to
treatment, both novel and established. In the present study we
investigated the ratio of circulating nitric oxide to endothelin-1 in
patients with both SSc and PAH, and determined whether
polymorphisms in NOS2 (the nitric oxide synthase 2 gene) are
associated with susceptibility to PAH. Endothelin-1 in plasma
and nitric oxide metabolites (nitrate and nitrite) in serum were
measured. The nitric oxide/endothelin-1 ratio was significantly
lower in patients with both SSc and PAH than in patients with
SSc only or in healthy control individuals. We confirmed the
presence of two single nucleotide polymorphisms at positions -
1,026 and -277 and a pentanucleotide repeat (CCTTT) at -2.5
kilobases. There were significant differences in single
nucleotide polymorphisms between patients with SSc who had
PAH and those who did not, and between patients with both
SSc and PAH and healthy control individuals. The CCTTT
repeat was significantly shorter in patients with both SSc and
PAH than in patients with SSc only or in healthy control
individuals. Transcriptional activity were analyzed using the
luciferase reporter assay. The transcriptional activity of NOS2
was much greater in fibroblasts transfected by a vector with a
long allele of the CCTTT repeat than in those transfected by a
vector with a short allele. Polymorphisms in the NOS2 gene are
associated with transcriptional activity of the NOS2 gene and
with susceptibility to SSc-related PAH.
Introduction
Systemic sclerosis (SSc) is an autoimmune disease of
unknown aetiology that is characterized by extensive fibrosis
of skin and visceral organs, and dysfunction of vascular tone
[1]. In its more severe forms, cardiac involvement and respira-
tory involvement are the most significant determinants of out-
come [2]. In particular, pulmonary hypertension is a fatal
complication in both diffuse and limited cutaneous SSc [3].
Pulmonary hypertension is generally divided into four major
categories: pulmonary arterial hypertension (PAH), pulmonary
hypertension associated with left-sided heart disease, pulmo-
nary hypertension associated with lung disease or hypoxae-
mia, and pulmonary hypertension due to chronic thrombotic or
embolic disease [4]. A major part of pulmonary hypertension
as it pertains to SSc corresponds with the pathophysiology of
PAH, a disease of the small pulmonary arteries characterized
by vascular proliferation, vasoconstriction, remodelling of the
pulmonary vessel wall and thrombosis in vessels.
Vasodilators such as nitric oxide (NO) and prostacyclin, along
with prolonged overexpression of vasoconstrictors such as
endothelin (ET)-1, not only affect vascular tone but also pro-
mote vascular remodelling, both of which have been impli-
cated in the pathogenesis of PAH [5-12]. Previous studiesPage 1 of 10
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SSc, especially in those with SSc complicated by PAH
[13,14]. However, reported levels of circulating NO in patients
with SSc are inconsistent, with several studies [15-18] finding
increased levels of NO in patients with SSc and others
[19,20] finding low levels, similar to those in healthy individu-
als. In our previous study [21] NO levels were markedly ele-
vated in patients with early-stage diffuse cutaneous SSc,
especially when the SSc was accompanied by active alveoli-
tis, but concentrations of NO in serum were low in late-stage
limited cutaneous SSc. No patients suffered the complication
of PAH in that study. Characteristic levels of NO and NO/ET-
1 ratio in patients with both SSc and PAH remain to be
established.
NO is an endothelial-derived relaxing factor that is synthesized
from L-arginine by nitric oxide synthase (NOS) [22]. Three iso-
forms of NOS have been identified [23]: NOS-1 (neuronal
NOS), NOS-2 (inducible NOS) and NOS-3 (endothelial
NOS). NOS-2 is the major source of NO production in condi-
tions involving exposure to cytokines; this is because it is
induced by a variety of cell types, including the proinflamma-
tory cytokines interleukin-1, tumour necrosis factor-α,
interferon-γ, and ET-1 [24].
Two randomized, double-blind, placebo-controlled trials
[25,26] evaluated the efficacy of the ET receptor antagonist
bosentan in patients with PAH that was either primary or asso-
ciated with SSc. Another therapeutic strategy in PAH is to
increase the activity of endogenous NO, which enhances NO-
dependent cGMP-mediated pulmonary vasodilatation through
inhibition of the breakdown of cGMP by phosphodiesterase
type 5 [27]. Although long-term inhaled NO therapy has
shown only a small benefit in patients with PAH [28], phos-
phodiesterase type 5 inhibitors (for example, sildenafil) have
been found to improve pulmonary artery pressure in patients
with PAH [29].
Because these novel therapies were developed to prolong
survival and improve patients' quality of life, we speculate that
an imbalance between ET-1 and NO is key to the pathogene-
sis of SSc complicated by PAH. Polymorphisms in the NOS2
gene promoter are thought to regulate its transcription activity,
which is reportedly associated with susceptibility to type 1 dia-
betes [30] and atopy [31] and with protection against malaria
[32]. In the present study we determined the levels of ET-1
and NO in blood from patients with SSc with or without PAH,
and we investigated the association between gene polymor-
phisms in NOS2 and susceptibility to PAH.
Materials and methods
Study patients
Twenty patients with SSc complicated by PAH were recruited.
All had been admitted to Aoyama Hospital of Tokyo Women's
Medical University or Kitasato University Hospital. As a dis-
ease control group, 58 patients with SSc but not PAH were
selected from patients admitted to Aoyama Hospital. Detailed
clinical characteristics of all patients are shown in Table 1. All
patients with SSc were of Japanese origin, met the criteria
established by the American College of Rheumatology for SSc
[33], and were classified as having either diffuse or limited
cutaneous SSc according to the classification proposed by
LeRoy and coworkers [34]. Ninety-five DNA samples were
obtained from healthy volunteers who were unrelated individu-
als of Japanese origin. All DNA samples were collected, with
approvals granted by the appropriate ethical committees of
Tokyo Women's Medical University, Kitasato University
School of Medicine, and Saitama Medical School.
We identified the presence of a complication of PAH in the fol-
lowing manner. All patients with SSc were first evaluated by
Doppler echocardiography, and then cardiac catheterization
was performed when right ventricular systolic pressure was
greater than 30 mmHg, based on Doppler echocardiography.
PAH was diagnosed in patients with SSc who satisfied the
modified US National Institutes of Health criteria for PAH after
cardiac catheterization [35], specifically mean pulmonary
artery pressure above 25 mmHg at rest or 30 mmHg after
exercise, with normal pulmonary artery wedge pressure. The
complication of pulmonary fibrosis was identified using high-
resolution computed tomography of the chest. Patients with
the following complications were excluded: severe pulmonary
fibrosis, with functional vital capacity below 70%; left-sided
heart disease; chronic thrombotic or embolic disease; renal
failure, including a history of scleroderma renal crisis; hyper-
tension; and diabetes.
Measurement of plasma endothelin-1 and serum nitric 
oxide levels
Blood samples were obtained from 16 patients with both SSc
and PAH and from 26 patients with SSc without PAH who
were randomly selected from among patients with SSc who
donated DNA samples at the time of admission to Aoyama
Hospital with informed consent. No specific diet was given to
patients while they were hospitalized. Twenty healthy volun-
teers (normal control individuals) who had no history of dieting
or smoking gave informed consent to participate in the study
and gave blood samples. ET-1 levels were measured in
plasma using an enzyme-linked immunosorbent assay kit (R&D
Systems, Cambridge, MA, USA). Because serum NO is
quickly degraded into nitrite and nitrate, we measured the total
levels of these NO metabolites as indicators of NO level, using
a calorimetric assay kit (Cayman Chemical, Ann Arbor, MI,
USA).
Sequencing the NOS2 promoter region
Genomic DNA was extracted from the blood sample using a
DNA extraction kit (Qiagen, Valencia, CA, USA). For direct
sequencing, PCR was performed to amplify the promoter
region of the NOS2 gene from -100 to -1,335 bp. The forwardPage 2 of 10
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CAAC-3' and 5'-CCAAAGGGAGTGTCCCCAGCTT-3',
respectively. The sequences of the PCR products were ana-
lyzed using the ABI Prism 3100 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA).
Haplotype typing in pairs of NOS2 polymorphisms
We entered the genotype data into the PENHAPLO computer
program, developed by Ito and coworkers [36], to estimate
haplotype frequency in the population and to calculate the
posterior probability of diplotype distribution for each study
subject. This program was designed for haplotype typing
using a maximum likelihood estimation method based on the
expectation maximization algorithm under the assumption of
Hardy-Weinberg equilibrium for the population.
Analysis of variable numbers of the CCTTT repeat 
polymorphism of the NOS2 promoter region
Genomic DNA was amplified by PCR with the use of a FAM™-
labelled sense primer (5'-ACCCCTGGAAGCCTACAACT-
GCAT-3') and an antisense primer (5'-GCCACTGCAC-
CCTAGCCTGTCTCA-3'). The various alleles were resolved
by capillary electrophoresis on an ABI Prism 3100 Genetic
Analyzer System (Applied Biosystems). Allele sizes were cal-
culated using the GeneScan Analysis computer program, with
a GeneScan™-500 ROX™ size standard (Applied Biosystems)
as the internal size standard.
Table 1
Clinical characteristics of patients
Characteristic SSc patients Healthy controls
With PAH Without PAH
Number at entry (n (male:female) 20 (1:19) 58 (5:53) 95 (8:87)
Age (years; mean (range) 48.6 (17–80) 47.7 (19–77) 40.9 (22–78)
Diffuse SSc:limited SSc (n) 6:14 33:25
Disease duration (months; mean (range) 42.0 (6–130) 41.9 (5–120)
Pulmonary fibrosis (n (%) 6 (30) 31 (53)
Frequency of ANA (n (%)
Anti-U1-snRNP antibody 11 (55) 17 (29) 0
Anti-topoisomerase I antibody 1 (5) 13 (22) 0
Anti-centromere antibody 5 (25) 12 (21) 0
ANA, antinuclear antibody; PAH, pulmonary arterial hypertension; SSc, systemic sclerosis.
Table 2
Distribution of single nucleotide polymorphisms in NOS2 gene promoter region
Subjects -1,026 bp -277 bp Haplotype
G/G G/T T/T A/A A/G G/G GA TA GG TG
SSc with 
PAH (n = 
20)
20 (100) 0 0 20 (100) 0 0 40 0 0 0
SSc 
without 
PAH (n = 
58)
43 (74) 11 (19) 4 (7) 43 (74) 10 (17) 5 (9) 96 0 1 19
Healthy 
controls (n 
= 95)
69 (73) 23 (24) 3 (3) 73 (77) 19 (20) 3 (3) 161 0 4 25
Values indicate number (%) of genotype or number of haplotype, which consists of two SNPs at -1,026 and -277. There were significant 
differences between patients with SSc who did and those who did not have PAH in the distribution of two SNPs at -277 and -1,026 (both P = 
0.04, by Fisher's exact test). Comparing the distribution of two SNPs between patients with SSc complicated by PAH and healthy control 
individuals, there was a significant difference at -1,026 (P = 0.02), but there was no difference at -277 (P = 0.053). With respect to haplotype, the 
frequency of GA was significantly higher in SSc with PAH than in SSc without PAH and in healthy control individuals (P = 0.001 and P = 0.02, 
respectively). PAH, pulmonary arterial hypertension; SNP, single nucleotide polymorphism; SSc, systemic sclerosis.Page 3 of 10
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fibroblasts
The 5' flanking region of the NOS2 gene (-1,557 to +58) was
prepared by PCR using a set of primers. The forward primer
(5'-GATTCTGACTCTTTCCCTGAG-3') is located -1,557 bp
from the transcription start site, and the reverse primer (5'-
GGAATGAGGCTGAGTTCTCTGCGGC-3') is located +58
bp from the transcription start site. Genomic DNA containing
the T/G allele at -1026 bp from the transcription start site of
the NOS2 gene was used as a PCR template. The PCR prod-
uct was inserted into a pGL3-Basic Vector (Promega, Madi-
son, WI, USA) that contained the firefly luciferase reporter
element, and all constructs were sequenced using the pGL3
forward and reverse sequencing primers. The pGL3 vectors
with T or G at -1,026 bp are referred to as pGL3-T and pGL3-
G, respectively, as shown in Figure 1. The sequences of
inserts of pGL3-T and pGL3-G were confirmed by direct
sequencing. Each vector of pGL3-T and pGL3-G had allele G
and allele A at -277 bp, respectively. The 6, 8, 10, 12 and 14
repeats of the pentanucleotide (CCTTT) region were obtained
by PCR using forward (5'-ACCCCTGGAAGCCTACAACT-
GCAT-3') and reverse (5'-GCCACTGCACCCTAGCCT-
GTCTCA-3') primers. The PCR products were cloned into the
upstream of the inserted NOS2 gene promoter in pGL3-T and
pGL3-G. The resulting constructs were named pGL3-T6,
pGL3-G6, pGL3-T8, pGL3-G8, pGL3-T10, pGL3-G10,
pGL3-T12, pGL3-G12, pGL3-T14 and pGL3-G14, and con-
tain 6, 8, 10, 12 and 14 repeats, respectively.
Human fibroblasts from three healthy individuals were cultured
in Dulbecco's modified Eagle's medium (DMEM) with 10%
foetal bovine serum (FBS; Sigma, St. Louis, MO, USA). For
transient transfections, fibroblasts were cultured in six-well
plates with 3 ml Opti-MEM (Invitrogen) containing 4 µg DNA
(pGL3 and phRL-TK vectors) and 12 µl Lipofectamine 2000
(Invitrogen). After 4 hours, 3 ml DMEM with 20% FBS in the
presence or absence of recombinant interleukin-1β (10 ng/ml;
R&D Systems) was added. The medium was changed after 16
hours to DMEM with 10% FBS in the presence or absence of
interleukin-1β (5 ng/mL). After an additional 24 hours of cul-
ture, the cells were washed twice using cold phosphate-buff-
ered saline and were harvested. Firefly and Renilla luciferase
activities were measured using the Dual-Glo Luciferase Assay
System (Promega). Fibroblasts were cotransfected with a
constitutively active Renilla luciferase vector (phRL-TK), and
firefly luciferase activity was normalized by Renilla luciferase
activity.
Statistics
Circulating ET-1 and NO concentrations are given as mean ±
standard deviation, and data were compared using the Stu-
dent's t test. We assessed the significance of the -277A/G
and -1026G/T single nucleotide polymorphisms (SNPs) by
the Fisher exact test. The relationship between the NO/ET-1
ratio and summed CCTTT repeat length was analyzed using
linear regression analysis. An allelic distribution of the number
of CCTTT repeats was compared using the Mann-Whitney U
test. P < 0.05 was considered statistically significant.
Figure 1
A schematic construct of the promoterless pGL3-basic vector. The luciferase vector (pGL3) was inserted with variable numbers of CCTTT repeats 
and the 1.5 kb minimal human NOS2 promoter region (-1,557 to +58 bp). The promoter region contained either T or G at -1026 bp (referred to as 
pGL3-T and pGL3-G, respectively). Each vector of pGL3-T and pGL3-G had allele G and allele A at -277 bp, respectively. The 6, 8, 10, 12, and 14 
repeats of the pentanucleotide (CCTTT) region were obtained by PCR. The resulting constructs were named pGL3-T6, pGL3-G6, pGL3-T8, pGL3-
G8, pGL3-T10, pGL3-G10, pGL3-T12, pGL3-G12, pGL3-T14 and pGL3-G14 and contain 6, 8, 10, 12 and 14 repeats, respectively. bp, base 
pairs; kb, kilobases; SNP, single nucleotide polymorphism; VNTR, variable numbers of tandem repeat.Page 4 of 10
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Circulating endothelin-1 and nitric oxide concentrations
Plasma ET-1 levels were significantly higher in each SSc
group than in healthy control individuals (1.4 ± 0.4 pg/ml), as
shown in Figure 2a. Moreover, ET-1 levels in patients with both
SSc and PH were significantly higher than in patients with
SSc but not PAH (4.1 ± 1.7 versus 2.2 ± 0.8 pg/ml; P <
0.001). In contrast, NO levels in patients with both SSc and
PAH (114 ± 28 µmol/l) were similar to those in healthy control
individuals (95 ± 30 µmol/l), but NO levels in patients with
SSc but not PAH (194 ± 89 µmol/l) were significantly higher
than in the other two groups (Figure 2b). The NO/ET-1 ratio
was significantly lower in patients with both SSc and PAH
(32.6 ± 15.7; n = 16) than in patients with SSc but not PAH
(87.8 ± 25.0; n = 26) and healthy control individuals (73.6 ±
35.7; n = 20), as shown in Figure 2c.
Determination of single nucleotide polymorphisms in 
the NOS2 promoter region
We genotyped the 78 patients with SSc and the 95 control
individuals for the promoter region (-100 to -1335 bp) of the
NOS2 gene by direct DNA sequencing. We confirmed the
presence of two previously reported SNPs at positions -277
and -1026 (Figure 3). The distribution of genotypes is shown
in Table 1. The distribution of genotypes at -1026 and -277
was significantly different between patients with SSc who had
Figure 2
Circulating levels of ET-1 and NO. (a) Plasma levels of ET-1 were measured in patients with SSc with or without PAH. (b) Serum levels of NO 
metabolites were measured. (c) The ratios of NO/ET-1 are shown. Data are expressed as mean ± standard deviation. ET, endothelin; NO, nitric 
oxide; NS, not significant; PAH, pulmonary arterial hypertension; SSc, systemic sclerosis.Page 5 of 10
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Fisher's exact test), but there was no difference between
patients with SSc who did not have PAH and healthy control
individuals in the distribution of genotypes at two SNPs.
Between healthy control individuals and patients with both
SSc and PAH, there was a significant difference in the distri-
bution of genetypes at -1026 (P = 0.02); in contrast, there
was no difference at -277 (P = 0.053).
Haplotype typing of the NOS2 promoter region
We typed the haplotype of the gene, which consists of two
SNPs at positions -1,026 and -277. The two SNPs were found
to be in linkage disequilibrium. We identified three haplotypes
using genes from patients with SSc and healthy control indi-
viduals: GA, GG, and TG (Table 2). The frequency of haplo-
type GA was significantly higher in patients with both SSc and
PAH than in patients with SSc but not PAH and in healthy indi-
viduals (P = 0.001 and P = 0.02, respectively), as shown in
Table 2.
Distribution of variable numbers of tandem repeat in the 
NOS2 promoter region
The 15 alleles found in the present study had 6–21 repeats,
and the distribution was significantly different between
patients with SSc and PAH and healthy control individuals (P
< 0.0001) and between patients with SSc with PAH and
those with without PAH (P < 0.0001), as shown in Table 3. In
contrast, there was no significant difference in distribution
between patients with SSc but not PAH and healthy control
individuals. If CCTTT repeat length strongly influences NOS2
transcription, then we would expect there to be a significant
correlation between CCTTT repeat length and serum NO lev-
els or NO/ET-1 ratios. We calculated the number of summed
CCTTT repeats and then analyzed the correlation between
that number and serum NO levels or NO/ET-1 ratios. As
shown in Figure 4, there was a significant correlation between
summed repeat length and both serum NO levels (r = 0.51, P
< 0.01; linear regression analysis) and NO/ET-1 ratios (r =
0.83, P < 0.0001) in all patients with SSc. However, in healthy
control individuals we identified no significant correlation (data
not shown).
Effects of NOS2 polymorphisms on transcriptional 
activity of the gene
To determine whether the polymorphisms of -277 SNP and -
1,026 SNP and variable numbers of tandem repeat were asso-
ciated with transcription of the NOS2 gene, we evaluated pro-
moter activities using the series of NOS2 promoter-luciferase
constructs (as described under Materials and method, above).
As shown in Figure 5, NOS2 was almost transcriptionally
silent in fibroblasts without stimuli. In contrast, transcription
was induced in fibroblasts transfected with vectors, including
promoter regions of the NOS2 gene, under stimulation by
interleukin-1β. The relative luciferase activities gradually
increased with increasing number of CCTTT repeats in both
alleles G and T at -1,026. In the case of the same number of
CCTTT repeats, the relative luciferase activity was higher in
vectors that included the promoter region with allele T at -
1,026 than in vectors that included the promoter region with
allele G. These findings indicate that transcriptional activity of
the NOS gene that includes G at -1,026 and a small number
of tandem repeats was low.
Discussion
In the present study were found that concentrations of NO
metabolites were not increased in patients with both SSc and
PAH, although plasma ET-1 levels were markedly elevated.
Our previous report [21] indicates that serum levels of NO
metabolites were significantly higher in patients with SSc than
in healthy control individuals, especially in patients with a dif-
fuse cutaneous type, active fibrosing alveolitis, or a short dura-
tion since onset. However, the population considered in that
study did not include patients with PAH, which could explain
why the present findings are inconsistent with those of the pre-
vious report. Although a number of reports have been pub-
lished concerning concentrations of ET-1 or NO in the
circulation of patients with SSc [8,13-21], this report is the
first to describe an imbalance in the NO/ET-1 ratio in patients
with PAH.
Over the past decade abnormalities in NO synthesis have
been proposed as being important in the pathogenesis and
development of pulmonary hypertension, especially primary
pulmonary hypertension (PPH). Initially, immunohistochemical
studies showed that pulmonary hypertension was associated
Figure 3
Polymorphisms of the 5' flanking region of the human NOS2 gene' fl i  r i  f t  hu an 2 gene. TATA sequence begins at position -30 bp from the transcription start site of exon 
1. bp, base pairs; SNP, single nucleotide polymorphism.Page 6 of 10
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studies found increase in expression of NOS-3 in patients with
pulmonary hypertension and in animal models of pulmonary
hypertension [38,39]. Despite these contradictory findings, it
has been reported that NO levels in blood and the lungs were
precisely decreased in patients with PPH and collagen dis-
ease related PAH [8-12]. Furthermore, it was determined that
NOS-dependent endogenous NO synthesis was decreased in
patients with PPH, which suggests that NOS activity may be
diminished in patients with PPH [40]. Lung inflammation lead-
Figure 4
Relationship between NO levels or NO/ET-1 ratios and summed CCTTT repeat length. The association study between summed lengths of the 
CCTTT repeat and (a) serum NO levels and (b) NO/ET-1 ratios was performed in 16 patients with SSc with PAH (open circles) and 26 patients 
with SSc without PAH (black triangles). The results of linear regression analysis of the data are represented by the solid line. Serum NO levels and 
NO/ET-1 ratios were significantly correlated with summed CCTTT repeat lengths (r = 0.51, P < 0.01; and r = 0.83, P < 0.0001, respectively). ET, 
endothelin; NO, nitric oxide; PAH, pulmonary arterial hypertension; SSc, systemic sclerosis.
Figure 5
Luciferase reporter assay of the NOS2 promoter with gene polymorphisms. The (a) pGL3-T vectors and (b) pGL3-G vectors were cloned by the 
NOS2 promoter region, including alleles T and G of the single nucleotide polymorphism at -1026 bp. In the series of pGL3-T or pGL3-G vectors, the 
6, 8, 10, 12 and 14 repeats of the CCTTT region were cloned upstream of the inserted NOS2 promoter in pGL3-T or pGL3-G. bp, base pairs; IL, 
interleukin.Page 7 of 10
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ute to the development of both PPH and SSc-related PAH
[41]. In the presence of increased levels of inflammatory medi-
ators, NOS activity may be dependent on production of NOS-
2, which is distinct from NOS-3 (the endothelial form of NOS)
because NOS-2 is inducible by inflammatory mediators, and
induced levels are much greater than levels of constitutive
NOS-3 production. Peripheral mononuclear cells and lesional
fibroblasts are capable of aberrant production of inflammatory
cytokines in patients with SSc [42-44]. These cytokines may
be involved not only in ET-1 synthesis by endothelial cells and
fibroblasts but also in induction of NOS-2. Also, excessive pro-
duction of ET-1 can mediate NOS-2 production through ET
receptor B [45]. Although evidence based on those biological
properties may promote speculation that levels of ET-1 corre-
late with levels of NO in the circulation, NO metabolite levels
were within normal range in patients with both SSc and PAH
patients whose serum contained much ET-1. We hypothesize
that this discrepancy may be explained by reduced NOS-2
production resulting from polymorphisms in the NOS2 gene.
As a result of sequencing the promoter region of the NOS2
gene from -100 to -1,335, we were able to confirm the pres-
ence of two SNPs, consistent with previous reports [46]. In
the present study, allele A at -277 SNP, allele G at -1,026 SNP
and shorter forms of the CCTTT repeat were associated with
susceptibility to PAH combined with SSc. The number of
CCTTT repeats was previously reported to influence transcrip-
tion of the NOS2 gene [47]. However, studies of variable num-
bers of tandem repeat both in vitro and in vivo have yielded
conflicting results [48]. To confirm whether those polymor-
phisms affect transcription of the NOS2 gene in fibroblasts,
we constructed a series of luciferase reporter vectors cloned
by various numbers of CCTTT combined with the promoter
region of the NOS2 gene from +58 to -1,557, which included
two kinds of haplotype.
Transcriptional activity was lowest in the NOS2 gene contain-
ing the six repeats of CCTTT and haplotype GA, which sug-
gests that transcription of the NOS2 gene might be little
induced by interleukin-1β in patients with SSc-related PAH.
Irrespective of whether patients with SSc had PAH, CCTTT
repeat length was well correlated with NO/ET-1 ratio. With
regard to the relationship between CCTTT repeat length and
serum NO levels, we found no significant difference among
SSc patients without PAH, although there were significant dif-
ferences among all SSc patients and among patients with
both SSc and PAH (data not shown). In the setting of aberrant
production of ET-1 or cytokines, NO synthesis via NOS-2
induction may be dependent on NOS2 gene polymorphisms.
In healthy control individuals, who had no vascular damage,
inflammation, or autoimmune disorders, there was no associa-
tion between CCTTT repeat length and either serum NO levels
or NO/ET-1 ratios (data not shown). Because NOS-2 induc-
tion is well controlled by ET-1 and cytokines, distinct from
NOS-3, which is constitutively produced, it has been sug-
gested that the CCTTT repeat length is more significantly cor-
related with NO/ET-1 ratios than with serum NO levels. Our
observations support the concept that the NOS2 gene poly-
morphism is a crucial factor in NO synthesis under conditions
of vascular damage and chronic inflammation, as well as PAH.
It is not possible to determine whether SSc patients without
PAH will suffer this complication in the future, and this is a lim-
itation of the present study. The patients enrolled in the study
are from a prospective cohort at our institution, and they have
been observed for clinical complications, including PAH, in the
follow-up clinic. None of the 58 patients with SSc but not PAH
has yet been diagnosed with PAH (mean duration of observa-
tion: 45 months).
Conclusion
NO is a key factor in generating PAH complicated by SSc, and
the decrease in NO synthesis might be attributable to reduced
NOS-2 production, which is dependent on NOS2 gene poly-
morphisms. Therapeutic options for PAH occurring as a com-
plication of SSc are limited; however, it is not usually the first
Table 3
Allele frequencies for the CCTTT-repeat polymorphism
Allele SSc patients Healthy 
controls
With PAH Without PAH
6 2 0 0
7 2 0 0
8 8 0 4
9 6 4 8
10 10 11 19
11 5 16 25
12 6 29 42
13 0 22 32
14 1 14 29
15 0 7 13
16 0 4 13
17 0 4 4
18 0 2 1
19 0 2 0
20 0 0 0
21 0 1 0
P < 0.0001 for patients with both SSc and PAH compared with 
healthy control subjects by the Mann-Whitney U test. P < 0.0001 for 
patients with both SSc and PAH compared with patients with SSc 
but not PAH by the Mann-Whitney U test. PAH, pulmonary arterial 
hypertension; SSc, systemic sclerosis.Page 8 of 10
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Available online http://arthritis-research.com/content/8/4/R104complication, and it develops several years after SSc is diag-
nosed. We believe that the development of means to predict
the occurrence of PAH related to SSc, and hence prevent this
complication, would be a great step forward. Although pro-
spective, longitudinal studies are needed, we propose that
patients with SSc who exhibit an imbalance between NO and
ET-1 production and who have a short length of CCTTT repeat
of the NOS2 gene can be treated with a phosphodiesterase
type 5 inhibitor before the occurrence of PAH.
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